To generate long term capital appreciation by investing predominantly in equity and equity related securities of the companies in Pharmaceuticals, Healthcare and allied sectors. There is no assurance that the investment objective of the Scheme will be achieved.
Expert-managed portfolios tailored to your financial goals and risk appetite.
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | -10.56% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -10.2% |
| Category returns | -7.54% | -3.42% | 10.54% | 13.4% | 8.01% | 3.9% | 18.22% | 18.48% | 12.78% | 13.01% | N/A |
| Absolute returns | -10.56% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -10.2% |
| Rank within category | 19/19 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sector Funds | 2026 |
|---|---|
| Yearly returns | N/A |
| Q1 returns | N/A |
| Q2 returns | N/A |
| Q3 returns | N/A |
| Q4 returns | -6.26% |
0.50% on or before 3M, NIL after 3M
| Alpha | -9.62785 |
| Beta | -0.3541 |
| Sharpe Ratio | -5.89186 |
| Sortino Ratio | -1.7986 |
| R-Squared | 0.1838 |
| Tracking Error | 2.8855 |
| Downside Risk | 7.125 |
| Std. Deviation (Annualised) | 4.8957 |
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Exp. Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HDFC Pharma and Healthcare Fund - Regular Plan - Growth | -8.18% | -2.85% | 13.49% | 19.65% | 16.65% | 26.3% | N/A | N/A | 26.16% | 3,501.37 | 2.11 | 0.45 | Very High |
| SBI Healthcare Opportunities Fund - Regular Plan - IDCW | -7.91% | -3.95% | 12% | 16.9% | 9.98% | 20.31% | 16% | 12.88% | 16.36% | 5,870.00 | 1.99 | 0.33 | Very High |
| UTI Healthcare Fund - Regular Plan - IDCW | -8.04% | -4.49% | 10.8% | 14.7% | 7.94% | 19.65% | 13.41% | 12.86% | 14.71% | 1,429.84 | 2.22 | 0.32 | Very High |
| Mirae Asset Healthcare Fund - Regular Plan - Growth | -6.65% | -2.37% | 10.95% | 15.8% | 10.86% | 19.1% | 13.11% | N/A | 19.31% | 3,494.44 | 2.04 | 0.30 | Very High |
| ICICI Prudential Healthcare Fund - Growth | -5.27% | -5.77% | 5.31% | 6.11% | 1.04% | 18.9% | 14.21% | N/A | 18.53% | 6,861.20 | 2.08 | 0.30 | Very High |
| LIC MF Healthcare Fund - Regular Plan - Growth | -8.31% | -3.16% | 10.44% | 10.22% | 4.45% | 18.2% | 9.97% | N/A | 16.14% | 99.36 | 2.67 | 0.28 | Very High |
| DSP Healthcare Fund - Regular Plan - Growth | -5.87% | -2.13% | 13.11% | 11.93% | 9.74% | 17.47% | 13.29% | N/A | 20.34% | 3,750.04 | 2.05 | 0.29 | Very High |
| Aditya Birla Sun Life Pharma & Healthcare Fund - Regular Plan - Growth | -7.92% | -5.04% | 8.82% | 11.15% | 7.84% | 16.89% | 11.54% | N/A | 18.16% | 1,077.52 | 2.29 | 0.27 | Very High |
| Quant Healthcare Fund - Regular Plan - Growth | -7.41% | -1.49% | 10.61% | 18.21% | 9.71% | 16.57% | N/A | N/A | 17.69% | 424.53 | 3.13 | 0.23 | Very High |
| Invesco India Pharma and Healthcare Fund - Regular Plan - Growth Current | -10.56% | 0% | 0% | 0% | N/A | N/A | N/A | N/A | -10.2% | 435.52 | 2.47 | -5.89 | Very High |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Triparty Repo | Cash & Cash Equivalents and Net Assets | 20.56% | |
| Max Healthcare Institute Ltd. | Healthcare Services | Domestic Equities | 9.58% |
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 8.99% |
| Sai Life Sciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 8.63% |
| Apollo Hospitals Enterprise Ltd. | Healthcare Services | Domestic Equities | 8.03% |
| Manipal Health Enterprises Ltd. | Healthcare Services | Domestic Equities | 7.98% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.85% |
| Global Health Ltd. | Healthcare Services | Domestic Equities | 7.00% |
| Dr. Agarwal's Health Care Ltd. | Healthcare Services | Domestic Equities | 6.32% |
| CORONA Remedies Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.13% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.93% |
| Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.86% |
| Krishna Institute of Medical Sciences Ltd | Healthcare Services | Domestic Equities | 4.72% |
| Aster DM Quality Care Ltd. | Healthcare Services | Domestic Equities | 1.99% |
| Net Receivables / (Payables) | Cash & Cash Equivalents and Net Assets | -7.57% | |
| Total | 100.00% | ||
Mr. Aditya Khemani has 8 Years of experience in research. He has held various positions in HSBC AMC and is associated with AMC since Oct 2007. Earlier to this he has worked with SBI Funds Management India Private Limited, Prudential ICICI Asset Management Company India Pvt Ltd., Morgan Stanley Advantage Services Private Limited in various positions.
Get personalized portfolio management services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
